Coronavirus subunit vaccine for presenting coronavirus receptor binding region based on virus-like particles
A virus-like, chikungunya virus technology, applied in the field of biomedicine, can solve the problems of unclear safety and weak immunogenicity
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0086] Example 1. Preparation of virus-like particles
[0087] 1. Construction of recombinant plasmids
[0088] The double-stranded DNA molecule shown in SEQ ID NO: 6 was substituted for the small fragment between KpnI and XhoI of the pcDNA3.1(+) vector to obtain the recombinant plasmid pcDNA3.1-CHIKV-VLP. The double-stranded DNA molecule shown in SEQ ID NO:6 encodes the CHIKV polyprotein shown in SEQ ID NO:2 (see the schematic diagram of the structural domain). figure 1 ). In the CHIKV polyprotein shown in SEQ ID NO: 2, the 1-261 amino acid residues constitute the capsid protein, the 262-321 amino acid residues constitute the E3 protein, and the 322-325 amino acid residues constitute the Furin cleavage site , amino acid residues 326-747 constitute E2 protein, amino acid residues 748-809 constitute 6K protein, and amino acid residues 810-1248 constitute E1 protein. CHIKV polyprotein is cleaved by host proteases to produce capsid protein, E1 protein, E2 protein, E3 protein, ...
Embodiment 2
[0111] Example 2. Evaluation of immune effect
[0112] Imject Alum: Thermo Scientific Corp, Cat. No. 77161.
[0113] The CHIKV-VLP solution or the CHIKV-RBD-Flag1-VLP solution prepared in Example 1 was used to adjust the protein concentration with PBS buffer at pH 7.4.
[0114] 1. Group immunization
[0115] Balb / c female mice aged 4-6 weeks were randomly divided into three groups with 3 mice in each group. Immunization process: the first immunization was performed on the first day of the experiment, and the booster immunization was performed on the 15th day of the experiment. Immunization methods are: right hind limb intramuscular injection. A single mouse was immunized with 100 μl of the immunized material at a time. CHIKV-VLP group: each 100 μl of the immune substance was emulsified by 50 μl of CHIKV-VLP solution (with a protein content of 2 μg) and 50 μl of aluminum glue adjuvant. CHIKV-RBD-Flag1-VLP group: each 100 μl of the immune substance was obtained by emulsific...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


